<DOC>
<DOCNO>EP-0634175</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Pharmaceutical combination, containing a renin-angiotensin-system inhibitor and an endothelin antagonist
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K4506	A61K3118	A61P912	A61K3116	A61K3155	A61K4500	A61K3116	A61K31505	A61K31435	A61P910	A61K31505	A61P900	A61P902	A61K31435	A61K3855	A61K3155	A61K3855	A61P900	A61K3118	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61K	A61P	A61P	A61K	A61K	A61K	A61K	A61P	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K45	A61K31	A61P9	A61K31	A61K31	A61K45	A61K31	A61K31	A61K31	A61P9	A61K31	A61P9	A61P9	A61K31	A61K38	A61K31	A61K38	A61P9	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Pharmaceutical combination products which contain an inhibitor of the renin-angiotensin system ("RAS inhibitor") and an endothelin antagonist are described. These products are suitable for controlling or preventing hypertension and its sequelae and for treating heart failure.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOFFMANN LA ROCHE
</APPLICANT-NAME>
<APPLICANT-NAME>
F. HOFFMANN-LA ROCHE AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
CLOZEL JEAN-PAUL
</INVENTOR-NAME>
<INVENTOR-NAME>
CLOZEL MARTINE
</INVENTOR-NAME>
<INVENTOR-NAME>
OSTERRIEDER WOLFGANG
</INVENTOR-NAME>
<INVENTOR-NAME>
CLOZEL, JEAN-PAUL
</INVENTOR-NAME>
<INVENTOR-NAME>
CLOZEL, MARTINE
</INVENTOR-NAME>
<INVENTOR-NAME>
OSTERRIEDER, WOLFGANG
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
A preparation, characterized in that it contains 4-tert-butyl-N-[(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulphonamide

and
cilazapril.
A preparation in accordance with claim 1 for use in the control or prevention
of hypertension and disorders resulting therefrom as well as in the treatment of cardiac

insufficiency.
A preparation according to either of claims 1-2, characterized in that the
weight ratio of RAS inhibitor from the ACE inhibitor group to the non-peptidic endothelin

antagonist is 1:1 to 1:500.
A preparation according to any one of claims 1-3, characterized in that it
contains 2.5 to 10 mg of a RAS inhibitor from the ACE inhibitor group and 250 to 1000 mg of

a non-peptidic endothelin antagonist.
A preparation according to any one of claims 1-4, characterized in that the
total weight of RAS inhibitor from the ACE inhibitor group and non-peptidic endothelin

antagonist is a maximum of 500 mg.
A commercial pack containing cilazapril and 4-tert-butyl-N-[(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulphonamide

together with instructions for the use of these active substances in combination for the
simultaneous, separate or chronologically spaced use in the control or prevention of

cardiovascular disorders, especially of hypertension and disorders resulting therefrom as well
as of cardiac insufficiency.
</CLAIMS>
</TEXT>
</DOC>
